Skip to main content

LabCorp Extends Bid for Orchid Cellmark for Seventh Time

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today announced it has extended its $85.4 million bid for Orchid Cellmark to 5 p.m. EDT Nov. 4.

It is the seventh time the proposed deal, in which LabCorp will pay $2.80 for each share of Orchid stock, has been extended. It previously had been extended to Oct. 7.

LabCorp received a request from the US Federal Trade Commission in May for additional information about the purchase and continues to cooperate with the agency's request.

The depositary for the tender offer has told LabCorp that as of 5 p.m. Oct. 7 EDT, shareholders of Orchid had validly tendered and not withdrawn 26,224,903 shares of the company's common stock, including 61,080 shares tendered through notices of guaranteed delivery.

The shares tendered represent about 87.4 percent of all outstanding shares of Orchid, and about 87.2 percent excluding the shares tendered by notices of guaranteed delivery.

On a fully diluted basis, the tendered shares represent about 80.2 percent of all outstanding shares and 80 percent excluding shares tendered by notices of guaranteed delivery.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.